Unknown

Dataset Information

0

Ultra?long acting insulin versus long?acting insulin for type 1 diabetes mellitus

ABSTRACT: Abstract This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effects of ultra?long acting insulin compared with long?acting insulin in patients with T1DM.

SUBMITTER: Ooi C 

PROVIDER: S-EPMC6513582 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
| S-EPMC8095010 | biostudies-literature
Unknown Insulin Degludec, a Novel Ultra-Long-Acting Basal Insulin versus Insulin Glargine for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis.
| S-EPMC6531575 | biostudies-literature
Unknown Effects of High-Intensity Interval Exercise versus Moderate Continuous Exercise on Glucose Homeostasis and Hormone Response in Patients with Type 1 Diabetes Mellitus Using Novel Ultra-Long-Acting Insulin.
| S-EPMC4552855 | biostudies-literature
Unknown Insulin detemir versus insulin glargine for type 2 diabetes mellitus.
| S-EPMC6486036 | biostudies-literature
Unknown Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.
| S-EPMC3041203 | biostudies-literature
Unknown A nationwide cohort study for comparative vascular safety of long-acting insulin analogue versus intermediate-acting human insulin in type 2 diabetes.
| S-EPMC7893071 | biostudies-literature
Unknown Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis.
| S-EPMC6317184 | biostudies-literature
Unknown Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus.
| S-EPMC3880476 | biostudies-literature
Unknown Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus.
| S-EPMC5425492 | biostudies-literature
Unknown A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial.
| S-EPMC3041205 | biostudies-literature